- Data Safety Monitoring Board recommends continuation of Peginterferon Lambda
- Interim analysis of 453 patients, randomized 1:1 Peginterferon Lambda vs placebo
PR Newswire
PALO ALTO, Calif., Sept. 20, 2021
PR Newswire
PALO ALTO, Calif., Sept. 20, 2021
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey